{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:37:31Z","timestamp":1794875851139,"version":"4.9.1"},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277087"],"award-info":[{"award-number":["22277087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Key Disease Diagnosis and Treatment Technique Project of Suzhou","award":["LCZX202310"],"award-info":[{"award-number":["LCZX202310"]}]},{"DOI":"10.13039\/501100014358","name":"New Medical Technology of Second Affiliated Hospital of Soochow University","doi-asserted-by":"publisher","award":["23ZL002"],"award-info":[{"award-number":["23ZL002"]}],"id":[{"id":"10.13039\/501100014358","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Development Project of Suzhou","award":["SYSD2020111"],"award-info":[{"award-number":["SYSD2020111"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Most of the antiviral drugs in the market are designed to target viral proteins directly.\nThey are generally considered safe for human use. However, they also suffer from several inherent\nlimitations, in particular, narrow-spectrum antiviral profiles and liability to drug resistance. The other\nstrategy for antiviral drug development is targeting host factors, which are highly involved at different\nstages in the viral life cycle. In contrast to direct-acting antiviral agents, host-targeting antiviral\nones normally exhibit broad-spectrum antiviral properties along with a much higher genetic barrier\nto drug resistance. Cyclin-dependent kinases (CDKs) represent one such host factor. In this review,\nwe summarized a number of CDK inhibitors (CDKIs) of varied chemical scaffolds with\ndemonstrated antiviral activity. Challenges and issues associated with the repurposing of CDKIs as\nantiviral agents were also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113895575311618240820103549","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:09:10Z","timestamp":1724666950000},"page":"178-189","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review"],"prefix":"10.2174","volume":"25","author":[{"given":"Miao","family":"Liu","sequence":"first","affiliation":[{"name":"Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, College of\nPharmaceutical Science, Soochow University, Suzhou, Jiangsu, 215021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal\nSurgery, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Ji","sequence":"additional","affiliation":[{"name":"Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, College of\nPharmaceutical Science, Soochow University, Suzhou, Jiangsu, 215021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/med.21664","volume":"40","author":"Ji X.","year":"2020","unstructured":"Ji X.; Li Z.; Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev  2020,40(5),1519-1557","journal-title":"Med Res Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","volume":"158","author":"Mason S.","year":"2018","unstructured":"Mason S.; Devincenzo J.P.; Toovey S.; Wu J.Z.; Whitley R.J.; Comparison of antiviral resistance across acute and chronic viral infections. Antiviral Res  2018,158,103-112","journal-title":"Antiviral Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/cid\/civ058","volume":"60","author":"Rogo T.","year":"2015","unstructured":"Rogo T.; DeLong A.K.; Chan P.; Kantor R.; Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island. Clin Infect Dis  2015,60(9),1426-1435","journal-title":"Clin Infect Dis"},{"key":"ref=4","first-page":"5447","volume":"9","author":"Woollard S.M.","year":"2015","unstructured":"Woollard S.M.; Kanmogne G.D.; Maraviroc: A review of its use in HIV infection and beyond. Drug Des Devel Ther  2015,9,5447-5468","journal-title":"Drug Des Devel Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eimc.2018.05.008","volume":"37","author":"Ram\u00edrez-Olivencia G.","year":"2019","unstructured":"Ram\u00edrez-Olivencia G.; Est\u00e9banez M.; Membrillo F.J.; Ybarra M.D.C.; Use of ribavirin in viruses other than hepatitis C. A review of the evidence. Enferm Infecc Microbiol Clin  2019,37(9),602-608","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00705-017-3511-1","volume":"162","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Jin F.; Wang R.; Li F.; Wu Y.; Kitazato K.; Wang Y.; HSP90: A promising broad-spectrum antiviral drug target. Arch Virol  2017,162(11),3269-3282","journal-title":"Arch Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/dna.2017.4033","volume":"37","author":"Schor S.","year":"2018","unstructured":"Schor S.; Einav S.; Repurposing of kinase inhibitors as broad-spectrum antiviral drugs. DNA Cell Biol  2018,37(2),63-69","journal-title":"DNA Cell Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-981-10-8727-1_19","volume":"1062","author":"Caputo A.T.","year":"2018","unstructured":"Caputo A.T.; Alonzi D.S.; Kiappes J.L.; Struwe W.B.; Cross A.; Basu S.; Darlot B.; Roversi P.; Zitzmann N.; Structural insights into the broad-spectrum antiviral target endoplasmic reticulum alpha-glucosidase II. Adv Exp Med Biol  2018,1062,265-276","journal-title":"Adv Exp Med Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"Rossignol J.F.","year":"2014","unstructured":"Rossignol J.F.; Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res  2014,110,94-103","journal-title":"Antiviral Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","volume":"18","author":"Mahmoud D.B.","year":"2020","unstructured":"Mahmoud D.B.; Shitu Z.; Mostafa A.; Drug repurposing of nitazoxanide: Can it be an effective therapy for COVID-19? J Genet Eng Biotechnol  2020,18(1),35-35","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res  2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4155\/fmc-2017-0246","volume":"10","author":"Heptinstall A.B.","year":"2018","unstructured":"Heptinstall A.B.; Adiyasa I.W.S.; Cano C.; Hardcastle I.R.; Recent advances in CDK inhibitors for cancer therapy. Future Med Chem  2018,10(11),1369-1388","journal-title":"Future Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14656566.2020.1738385","volume":"21","author":"Qin A.","year":"2020","unstructured":"Qin A.; Reddy H.G.; Weinberg F.D.; Kalemkerian G.P.; Cyclin-dependent kinase inhibitors for the treatment of lung cancer. Expert Opin Pharmacother  2020,21(8),941-952","journal-title":"Expert Opin Pharmacother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/095632020601700601","volume":"17","author":"Schang L.M.","year":"2006","unstructured":"Schang L.M.; St Vincent M.R.; Lacasse J.J.; Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother  2006,17(6),293-320","journal-title":"Antivir Chem Chemother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e57340","DOI":"10.1371\/journal.pone.0057340","volume":"8","author":"Cheng P.H.","year":"2013","unstructured":"Cheng P.H.; Rao X.M.; McMasters K.M.; Zhou H.S.; Molecular basis for viral selective replication in cancer cells: Activation of CDK2 by adenovirus-induced cyclin E. PLoS One  2013,8(2),e57340","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1128\/JVI.02196-09","volume":"84","author":"Gearhart T.L.","year":"2010","unstructured":"Gearhart T.L.; Bouchard M.J.; The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol  2010,84(6),2675-2686","journal-title":"J Virol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/092986711794839188","volume":"18","author":"N\u00e9meth G.","year":"2011","unstructured":"N\u00e9meth G.; Varga Z.; Greff Z.; Bencze G.; Sipos A.; Sz\u00e1ntai-Kis C.; Baska F.; Gyuris A.; Kelemenics K.; Szathm\u00e1ry Z.; Min\u00e1rovits J.; K\u00e9ri G.; Orfi L.; Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem  2011,18(3),342-358","journal-title":"Curr Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"10591","DOI":"10.1128\/JVI.01242-08","volume":"82","author":"Durand L.O.","year":"2008","unstructured":"Durand L.O.; Roizman B.; Role of CDK9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol  2008,82(21),10591-10599","journal-title":"J Virol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jac\/dkf227","volume":"50","author":"Schang L.M.","year":"2002","unstructured":"Schang L.M.; Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother  2002,50(6),779-792","journal-title":"J Antimicrob Chemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"28345","DOI":"10.1074\/jbc.C000446200","volume":"275","author":"Chao S.H.","year":"2000","unstructured":"Chao S.H.; Fujinaga K.; Marion J.E.; Taube R.; Sausville E.A.; Senderowicz A.M.; Peterlin B.M.; Price D.H.; Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem  2000,275(37),28345-28348","journal-title":"J Biol Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e79007","DOI":"10.1371\/journal.pone.0079007","volume":"8","author":"Ou M.","year":"2013","unstructured":"Ou M.; Sandri-Goldin R.M.; Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription. PLoS One  2013,8(10),e79007","journal-title":"PLoS One"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1089\/adt.2015.0003.drrr","volume":"13","author":"Perwitasari O.","year":"2015","unstructured":"Perwitasari O.; Yan X.; O\u2019Donnell J.; Johnson S.; Tripp R.A.; Repurposing kinase inhibitors as antiviral agents to control influenza A virus replication. Assay Drug Dev Technol  2015,13(10),638-649","journal-title":"Assay Drug Dev Technol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"11219","DOI":"10.1128\/JVI.78.20.11219-11232.2004","volume":"78","author":"Sanchez V.","year":"2004","unstructured":"Sanchez V.; McElroy A.K.; Yen J.; Tamrakar S.; Clark C.L.; Schwartz R.A.; Spector D.H.; Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J Virol  2004,78(20),11219-11232","journal-title":"J Virol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/acsinfecdis.7b00009","volume":"3","author":"Prasad V.","year":"2017","unstructured":"Prasad V.; Suomalainen M.; Hemmi S.; Greber U.F.; Cell cycle-dependent kinase CDK9 is a postexposure drug target against human adenoviruses. ACS Infect Dis  2017,3(6),398-405","journal-title":"ACS Infect Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1006\/viro.1999.9944","volume":"264","author":"Taube R.","year":"1999","unstructured":"Taube R.; Fujinaga K.; Wimmer J.; Barboric M.; Peterlin B.M.; Tat transactivation: A model for the regulation of eukaryotic transcriptional elongation. Virology  1999,264(2),245-253","journal-title":"Virology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1681\/ASN.V12122827","volume":"12","author":"Nelson P.J.","year":"2001","unstructured":"Nelson P.J.; Gelman I.H.; Klotman P.E.; Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J Am Soc Nephrol  2001,12(12),2827-2831","journal-title":"J Am Soc Nephrol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/jac\/dkg175","volume":"51","author":"Nelson P.J.","year":"2003","unstructured":"Nelson P.J.; D\u2019Agati V.D.; Gries J.M.; Suarez J.R.; Gelman I.H.; Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J Antimicrob Chemother  2003,51(4),921-929","journal-title":"J Antimicrob Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.030734","author":"Xing J.","year":"2020","unstructured":"Xing J.; Shankar R.; Drelich A.; Paithankar S.; Chekalin E.; Dexheimer T.; Rajasekaran S.; Tseng C-T.K.; Chen B.; Reversal of infected host gene expression identifies repurposed drug candidates for COVID-19. BioRxiv  2020","journal-title":"BioRxiv"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1074\/jbc.M002466200","volume":"276","author":"Leclerc S.","year":"2001","unstructured":"Leclerc S.; Garnier M.; Hoessel R.; Marko D.; Bibb J.A.; Snyder G.L.; Greengard P.; Biernat J.; Wu Y.Z.; Mandelkow E.M.; Eisenbrand G.; Meijer L.; Indirubins inhibit glycogen synthase kinase-3 beta and CDK5\/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer\u2019s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem  2001,276(1),251-260","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.apsb.2012.10.005","volume":"2","author":"Zhang D.","year":"2012","unstructured":"Zhang D.; Ji X.; Gao R.; Wang H.; Meng S.; Zhong Z.; Li Y.; Jiang J.; Li Z.; Synthesis and antiviral activities of a novel class of thioflavone and flavonoid analogues. Acta Pharm Sin B  2012,2(6),575-580","journal-title":"Acta Pharm Sin B"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"De Azevedo W.F.","year":"1997","unstructured":"De Azevedo W.F.; Leclerc S.; Meijer L.; Havlicek L.; Strnad M.; Kim S.H.; Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human CDK2 complexed with roscovitine. Eur J Biochem  1997,243(1-2),518-526","journal-title":"Eur J Biochem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00018-005-5185-1","volume":"62","author":"Kry\u0161tof V.","year":"2005","unstructured":"Kry\u0161tof V.; McNae I.W.; Walkinshaw M.D.; Fischer P.M.; M\u00fcller P.; Vojt\u011b\u0161ek B.; Ors\u00e1g M.; Havl\u00ed\u010dek L.; Strnad M.; Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci  2005,62(15),1763-1771","journal-title":"Cell Mol Life Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.281.5376.533","volume":"281","author":"Gray N.S.","year":"1998","unstructured":"Gray N.S.; Wodicka L.; Thunnissen A.M.W.H.; Norman T.C.; Kwon S.; Espinoza F.H.; Morgan D.O.; Barnes G.; LeClerc S.; Meijer L.; Kim S.H.; Lockhart D.J.; Schultz P.G.; Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science  1998,281(5376),533-538","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3851\/IMP1460","volume":"20","author":"Holcakova J.","year":"2010","unstructured":"Holcakova J.; Tomasec P.; Bugert J.J.; Wang E.C.Y.; Wilkinson G.W.G.; Hrstka R.; Krystof V.; Strnad M.; Vojtesek B.; The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother  2010,20(3),133-142","journal-title":"Antivir Chem Chemother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e89228","DOI":"10.1371\/journal.pone.0089228","volume":"9","author":"Holcakova J.","year":"2014","unstructured":"Holcakova J.; Muller P.; Tomasec P.; Hrstka R.; Nekulova M.; Krystof V.; Strnad M.; Wilkinson G.W.G.; Vojtesek B.; Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy. PLoS One  2014,9(2),e89228","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bbapap.2003.11.026","volume":"1697","author":"Moffat J.F.","year":"2004","unstructured":"Moffat J.F.; McMichael M.A.; Leisenfelder S.A.; Taylor S.L.; Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim Biophys Acta Proteins Proteomics  2004,1697(1-2),225-231","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.1128\/JVI.75.16.7266-7279.2001","volume":"75","author":"Wang D.","year":"2001","unstructured":"Wang D.; de la Fuente C.; Deng L.; Wang L.; Zilberman I.; Eadie C.; Healey M.; Stein D.; Denny T.; Harrison L.E.; Meijer L.; Kashanchi F.; Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol  2001,75(16),7266-7279","journal-title":"J Virol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1128\/JVI.73.10.8843-8847.1999","volume":"73","author":"Jordan R.","year":"1999","unstructured":"Jordan R.; Schang L.; Schaffer P.A.; Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. J Virol  1999,73(10),8843-8847","journal-title":"J Virol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"9352","DOI":"10.1128\/JVI.78.17.9352-9365.2004","volume":"78","author":"Diwan P.","year":"2004","unstructured":"Diwan P.; Lacasse J.J.; Schang L.M.; Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol  2004,78(17),9352-9365","journal-title":"J Virol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.virol.2007.08.034","volume":"370","author":"Orba Y.","year":"2008","unstructured":"Orba Y.; Sunden Y.; Suzuki T.; Nagashima K.; Kimura T.; Tanaka S.; Sawa H.; Pharmacological CDK inhibitor R-Roscovitine suppresses JC virus proliferation. Virology  2008,370(1),173-183","journal-title":"Virology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nm.4184","volume":"22","author":"Xu M.","year":"2016","unstructured":"Xu M.; Lee E.M.; Wen Z.; Cheng Y.; Huang W.K.; Qian X.; Tcw J.; Kouznetsova J.; Ogden S.C.; Hammack C.; Jacob F.; Nguyen H.N.; Itkin M.; Hanna C.; Shinn P.; Allen C.; Michael S.G.; Simeonov A.; Huang W.; Christian K.M.; Goate A.; Brennand K.J.; Huang R.; Xia M.; Ming G.; Zheng W.; Song H.; Tang H.; Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med  2016,22(10),1101-1107","journal-title":"Nat Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1006\/viro.1997.8489","volume":"231","author":"Bresnahan W.A.","year":"1997","unstructured":"Bresnahan W.A.; Boldogh I.; Chi P.; Thompson E.A.; Albrecht T.; Inhibition of cellular CDK2 activity blocks human cytomegalovirus replication. Virology  1997,231(2),239-247","journal-title":"Virology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.virol.2008.10.002","volume":"383","author":"Hale B.G.","year":"2009","unstructured":"Hale B.G.; Knebel A.; Botting C.H.; Galloway C.S.; Precious B.L.; Jackson D.; Elliott R.M.; Randall R.E.; CDK\/ERK-mediated phosphorylation of the human influenza A virus NS1 protein at threonine-215. Virology  2009,383(1),6-11","journal-title":"Virology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbrc.2020.04.034","volume":"526","author":"Huang Q.","year":"2020","unstructured":"Huang Q.; Zhong Y.; Li J.; Ye Y.; Wu W.; Chen L.; Feng M.; Yang J.; Liu S.; Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication. Biochem Biophys Res Commun  2020,526(4),1143-1149","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","volume":"46","author":"Le Tourneau C.","year":"2010","unstructured":"Le Tourneau C.; Faivre S.; Laurence V.; Delbaldo C.; Vera K.; Girre V.; Chiao J.; Armour S.; Frame S.; Green S.R.; Gianella-Borradori A.; Di\u00e9ras V.; Raymond E.; Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer  2010,46(18),3243-3250","journal-title":"Eur J Cancer"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbapap.2003.11.024","volume":"1697","author":"Schang L.M.","year":"2004","unstructured":"Schang L.M.; Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta Proteins Proteomics  2004,1697(1-2),197-209","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/MCB.00595-14","volume":"34","author":"Kelso T.W.R.","year":"2014","unstructured":"Kelso T.W.R.; Baumgart K.; Eickhoff J.; Albert T.; Antrecht C.; Lemcke S.; Klebl B.; Meisterernst M.; Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol  2014,34(19),3675-3688","journal-title":"Mol Cell Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/AAC.04534-14","volume":"59","author":"Hutterer C.","year":"2015","unstructured":"Hutterer C.; Eickhoff J.; Milbradt J.; Korn K.; Zeittr\u00e4ger I.; Bahsi H.; Wagner S.; Zischinsky G.; Wolf A.; Degenhart C.; Unger A.; Baumann M.; Klebl B.; Marschall M.; A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother  2015,59(4),2062-2071","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1172\/JCI73805","volume":"124","author":"Yamamoto M.","year":"2014","unstructured":"Yamamoto M.; Onogi H.; Kii I.; Yoshida S.; Iida K.; Sakai H.; Abe M.; Tsubota T.; Ito N.; Hosoya T.; Hagiwara M.; CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J Clin Invest  2014,124(8),3479-3488","journal-title":"J Clin Invest"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.antiviral.2016.08.008","volume":"133","author":"Tanaka T.","year":"2016","unstructured":"Tanaka T.; Okuyama-Dobashi K.; Murakami S.; Chen W.; Okamoto T.; Ueda K.; Hosoya T.; Matsuura Y.; Ryo A.; Tanaka Y.; Hagiwara M.; Moriishi K.; Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation. Antiviral Res  2016,133,156-164","journal-title":"Antiviral Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s13063-019-3570-6","volume":"20","author":"Nomura T.","year":"2019","unstructured":"Nomura T.; Sumi E.; Egawa G.; Nakajima S.; Toichi E.; Uozumi R.; Tada H.; Nakagawa T.; Hagiwara M.; Kabashima K.; The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial. Trials  2019,20(1),489","journal-title":"Trials"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40261-018-0712-7","volume":"39","author":"Sumi E.","year":"2019","unstructured":"Sumi E.; Nomura T.; Asada R.; Uozumi R.; Tada H.; Amino Y.; Sawada T.; Yonezawa A.; Hagiwara M.; Kabashima K.; Safety and plasma concentrations of a cyclin-dependent kinase 9 (CDK9) inhibitor, FIT039, administered by a single adhesive skin patch applied on normal skin and cutaneous Warts. Clin Drug Investig  2019,39(1),55-61","journal-title":"Clin Drug Investig"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"Chen P.","year":"2016","unstructured":"Chen P.; Lee N.V.; Hu W.; Xu M.; Ferre R.A.; Lam H.; Bergqvist S.; Solowiej J.; Diehl W.; He Y.A.; Yu X.; Nagata A.; VanArsdale T.; Murray B.W.; spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther  2016,15(10),2273-2281","journal-title":"Mol Cancer Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jsps.2018.03.005","volume":"26","author":"Bakir T.M.","year":"2018","unstructured":"Bakir T.M.; The role of SAMHD1 expression and its relation to HIV-2 (Vpx) gene production. Saudi Pharm J  2018,26(6),903-908","journal-title":"Saudi Pharm J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.celrep.2013.03.017","volume":"3","author":"Cribier A.","year":"2013","unstructured":"Cribier A.; Descours B.; Valad\u00e3o A.L.C.; Laguette N.; Benkirane M.; Phosphorylation of SAMHD1 by cyclin A2\/CDK1 regulates its restriction activity toward HIV-1. Cell Rep  2013,3(4),1036-1043","journal-title":"Cell Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.chom.2013.03.005","volume":"13","author":"White T.E.","year":"2013","unstructured":"White T.E.; Brandariz-Nu\u00f1ez A.; Valle-Casuso J.C.; Amie S.; Nguyen L.A.; Kim B.; Tuzova M.; Diaz-Griffero F.; The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe  2013,13(4),441-451","journal-title":"Cell Host Microbe"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1128\/JVI.00155-14","volume":"88","author":"St Gelais C.","year":"2014","unstructured":"St Gelais C.; de Silva S.; Hach J.C.; White T.E.; Diaz-Griffero F.; Yount J.S.; Wu L.; Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1. J Virol  2014,88(10),5834-5844","journal-title":"J Virol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1097\/QAD.0000000000000399","volume":"28","author":"Pauls E.","year":"2014","unstructured":"Pauls E.; Badia R.; Torres-Torronteras J.; Ruiz A.; Permanyer M.; Riveira-Mu\u00f1oz E.; Clotet B.; Marti R.; Ballana E.; Est\u00e9 J.A.; Palbociclib, a selective inhibitor of cyclin-dependent kinase4\/6, blocks HIV-1 reverse transcription through the control of sterile \u03b1 motif and HD domain-containing protein-1 (SAMHD1) activity. AIDS  2014,28(15),2213-2222","journal-title":"AIDS"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jac\/dkv363","volume":"71","author":"Badia R.","year":"2016","unstructured":"Badia R.; Angulo G.; Riveira-Mu\u00f1oz E.; Pujantell M.; Puig T.; Ramirez C.; Torres-Torronteras J.; Mart\u00ed R.; Pauls E.; Clotet B.; Ballana E.; Est\u00e9 J.A.; Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. J Antimicrob Chemother  2016,71(2),387-394","journal-title":"J Antimicrob Chemother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","volume":"12","author":"Corona S.P.","year":"2018","unstructured":"Corona S.P.; Generali D.; Abemaciclib: A CDK4\/6 inhibitor for the treatment of HR+\/HER2\u2013 advanced breast cancer. Drug Des Devel Ther  2018,12,321-330","journal-title":"Drug Des Devel Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers12030713","volume":"12","author":"Castellv\u00ed M.","year":"2020","unstructured":"Castellv\u00ed M.; Felip E.; Pharmacological modulation of SAMHD1 activity by CDK4\/6 inhibitors improves anticancer therapy. Cancers  2020,12(3),713","journal-title":"Cancers"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"Jeon S.","year":"2020","unstructured":"Jeon S.; Ko M.; Lee J.; Choi I.; Byun S.Y.; Park S.; Shum D.; Kim S.; Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother  2020,64(7),e00819-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0092-8674(76)90092-1","volume":"9","author":"Sehgal P.B.","year":"1976","unstructured":"Sehgal P.B.; Darnell J.E.; Tamm I.; The inhibition of DRB (5,6-dichloro-1-\u03b2-d-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells. Cell  1976,9(3),473-480","journal-title":"Cell"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.chembiol.2010.07.012","volume":"17","author":"Baumli S.","year":"2010","unstructured":"Baumli S.; Endicott J.A.; Johnson L.N.; Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem Biol  2010,17(9),931-936","journal-title":"Chem Biol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.11.20.2633","volume":"11","author":"Mancebo H.S.Y.","year":"1997","unstructured":"Mancebo H.S.Y.; Lee G.; Flygare J.; Tomassini J.; Luu P.; Zhu Y.; Peng J.; Blau C.; Hazuda D.; Price D.; Flores O.; P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev  1997,11(20),2633-2644","journal-title":"Genes Dev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1021\/jm00020a025","volume":"38","author":"Townsend L.B.","year":"1995","unstructured":"Townsend L.B.; Devivar R.V.; Turk S.R.; Nassiri M.R.; Drach J.C.; Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J Med Chem  1995,38(20),4098-4105","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/9035","volume":"1","author":"Hoessel R.","year":"1999","unstructured":"Hoessel R.; Leclerc S.; Endicott J.A.; Nobel M.E.M.; Lawrie A.; Tunnah P.; Leost M.; Damiens E.; Marie D.; Marko D.; Niederberger E.; Tang W.; Eisenbrand G.; Meijer L.; Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol  1999,1(1),60-67","journal-title":"Nat Cell Biol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1021\/acs.jmedchem.7b00324","volume":"60","author":"Cheng X.","year":"2017","unstructured":"Cheng X.; Merz K.H.; Vatter S.; Zeller J.; Muehlbeyer S.; Thommet A.; Christ J.; W\u00f6lfl S.; Eisenbrand G.; identification of a water-soluble indirubin derivative as potent inhibitor of insulin-like growth factor 1 receptor through structural modification of the parent natural molecule. J Med Chem  2017,60(12),4949-4962","journal-title":"J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1097\/01.aids.0000194805.74293.11","volume":"19","author":"Heredia A.","year":"2005","unstructured":"Heredia A.; Davis C.; Bamba D.; Le N.; Gwarzo M.Y.; Sadowska M.; Gallo R.C.; Redfield R.R.; Indirubin-3\u2032-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS  2005,19(18),2087-2095","journal-title":"AIDS"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2014.03.019","volume":"106","author":"Mok C.K.P.","year":"2014","unstructured":"Mok C.K.P.; Kang S.S.R.; Chan R.W.Y.; Yue P.Y.K.; Mak N.K.; Poon L.L.M.; Wong R.N.S.; Peiris J.S.M.; Chan M.C.W.; Anti-inflammatory and antiviral effects of indirubin derivatives in influenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Res  2014,106,95-104","journal-title":"Antiviral Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"18941","DOI":"10.1038\/srep18941","volume":"6","author":"Kwok H.H.","year":"2016","unstructured":"Kwok H.H.; Poon P.Y.; Fok S.P.; Ying-Kit Yue P.; Mak N.K.; Chan M.C.W.; Peiris J.S.M.; Wong R.N.S.; Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells. Sci Rep  2016,6(1),18941-18941","journal-title":"Sci Rep"},{"key":"ref=72","first-page":"45","volume":"24","author":"Chan M.C.","year":"2018","unstructured":"Chan M.C.; Chan R.W.; Mok C.K.; Mak N.K.; Wong R.N.; Indirubin-3'-oxime as an antiviral and immunomodulatory agent in treatment of severe human influenza virus infection. Hong Kong Med J  2018,24(Suppl 6)(5),45-47","journal-title":"Hong Kong Med J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bmc.2005.08.008","volume":"14","author":"Moon M.J.","year":"2006","unstructured":"Moon M.J.; Lee S.K.; Lee J.W.; Song W.K.; Kim S.W.; Kim J.I.; Cho C.; Choi S.J.; Kim Y.C.; Synthesis and structure\u2013activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem  2006,14(1),237-246","journal-title":"Bioorg Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1021\/jm031016d","volume":"47","author":"Polychronopoulos P.","year":"2004","unstructured":"Polychronopoulos P.; Magiatis P.; Skaltsounis A.L.; Myrianthopoulos V.; Mikros E.; Tarricone A.; Musacchio A.; Roe S.M.; Pearl L.; Leost M.; Greengard P.; Meijer L.; Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem  2004,47(4),935-946","journal-title":"J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"11429","DOI":"10.1038\/s41598-020-68134-8","volume":"10","author":"Dan N.T.","year":"2020","unstructured":"Dan N.T.; Quang H.D.; Van Truong V.; Huu Nghi D.; Cuong N.M.; Cuong T.D.; Toan T.Q.; Bach L.G.; Anh N.H.T.; Mai N.T.; Lan N.T.; Van Chinh L.; Quan P.M.; Design, synthesis, structure, in vitro cytotoxic activity evaluation and docking studies on target enzyme GSK-3\u03b2 of new indirubin-3\u02b9-oxime derivatives. Sci Rep  2020,10(1),11429","journal-title":"Sci Rep"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"118767","DOI":"10.1016\/j.bbamcr.2020.118767","volume":"1867","author":"Alfhili M.A.","year":"2020","unstructured":"Alfhili M.A.; Alsughayyir J.; McCubrey J.A.; Akula S.M.; GSK-3-associated signaling is crucial to virus infection of cells. Biochim Biophys Acta Mol Cell Res  2020,1867(10),118767","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1517\/13543784.2014.948152","volume":"23","author":"Criscitiello C.","year":"2014","unstructured":"Criscitiello C.; Viale G.; Esposito A.; Curigliano G.; Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs  2014,23(9),1305-1312","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1172\/JCI94586","volume":"128","author":"Hossain D.M.S.","year":"2018","unstructured":"Hossain D.M.S.; Javaid S.; Cai M.; Zhang C.; Sawant A.; Hinton M.; Sathe M.; Grein J.; Blumenschein W.; Pinheiro E.M.; Chackerian A.; Dinaciclib induces immunogenic cell death and enhances anti-PD1\u2013mediated tumor suppression. J Clin Invest  2018,128(2),644-654","journal-title":"J Clin Invest"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.dnarep.2009.04.016","volume":"8","author":"Chaurushiya M.S.","year":"2009","unstructured":"Chaurushiya M.S.; Weitzman M.D.; Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair  2009,8(9),1166-1176","journal-title":"DNA Repair"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","volume":"182","author":"Bouhaddou M.","year":"2020","unstructured":"Bouhaddou M.; Memon D.; Meyer B.; White K.M.; Rezelj V.V.; Correa Marrero M.; Polacco B.J.; Melnyk J.E.; Ulferts S.; Kaake R.M.; Batra J.; Richards A.L.; Stevenson E.; Gordon D.E.; Rojc A.; Obernier K.; Fabius J.M.; Soucheray M.; Miorin L.; Moreno E.; Koh C.; Tran Q.D.; Hardy A.; Robinot R.; Vallet T.; Nilsson-Payant B.E.; Hernandez-Armenta C.; Dunham A.; Weigang S.; Knerr J.; Modak M.; Quintero D.; Zhou Y.; Dugourd A.; Valdeolivas A.; Patil T.; Li Q.; H\u00fcttenhain R.; Cakir M.; Muralidharan M.; Kim M.; Jang G.; Tutuncuoglu B.; Hiatt J.; Guo J.Z.; Xu J.; Bouhaddou S.; Mathy C.J.P.; Gaulton A.; Manners E.J.; F\u00e9lix E.; Shi Y.; Goff M.; Lim J.K.; McBride T.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klippsten S.; De wit, E.; Leach, A.R.; Kortemme, T.; Shoichet, B.; Ott, M.; Saez-Rodriguez, J.; tenOever, B.R.; Mullins, R.D.; Fischer, E.R.; Kochs, G.; Grosse, R.; Garc\u00eda-Sastre, A.; Vignuzzi, M.; Johnson, J.R.; Shokat, K.M.; Swaney, D.L.; Beltrao, P.; Krogan, N.J. The global phosphorylation landscape of SARS-CoV-2 infection. Cell  2020,182(3),685-712.e19","journal-title":"Cell"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1021\/jm800382h","volume":"51","author":"Wyatt P.G.","year":"2008","unstructured":"Wyatt P.G.; Woodhead A.J.; Berdini V.; Boulstridge J.A.; Carr M.G.; Cross D.M.; Davis D.J.; Devine L.A.; Early T.R.; Feltell R.E.; Lewis E.J.; McMenamin R.L.; Navarro E.F.; O\u2019Brien M.A.; O\u2019Reilly M.; Reule M.; Saxty G.; Seavers L.C.A.; Smith D.M.; Squires M.S.; Trewartha G.; Walker M.T.; Woolford A.J.A.; Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem  2008,51(16),4986-4999","journal-title":"J Med Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.1073\/pnas.96.13.7208","volume":"96","author":"Flores O.","year":"1999","unstructured":"Flores O.; Lee G.; Kessler J.; Miller M.; Schlief W.; Tomassini J.; Hazuda D.; Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci USA  1999,96(13),7208-7213","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2017.02.008","volume":"141","author":"Buchmann B.","year":"2017","unstructured":"Buchmann B.; D\u00f6hner K.; Schirdewahn T.; Sodeik B.; Manns M.P.; Wedemeyer H.; Ciesek S.; von Hahn T.; A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antiviral Res  2017,141,116-123","journal-title":"Antiviral Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/npjsba.2016.15","volume":"2","author":"Duan Q.","year":"2016","unstructured":"Duan Q.; Reid S.P.; Clark N.R.; Wang Z.; Fernandez N.F.; Rouillard A.D.; Readhead B.; Tritsch S.R.; Hodos R.; Hafner M.; Niepel M.; Sorger P.K.; Dudley J.T.; Bavari S.; Panchal R.G.; Ma\u2019ayan A.; L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst Biol Appl  2016,2(1),16015","journal-title":"NPJ Syst Biol Appl"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11802-014-2324-z","volume":"13","author":"Ma X.","year":"2014","unstructured":"Ma X.; Zhu T.; Gu Q.; Xi R.; Wang W.; Li D.; Structures and antiviral activities of butyrolactone derivatives isolated from Aspergillus terreus MXH-23. J Ocean Univ China  2014,13(6),1067-1070","journal-title":"J Ocean Univ China"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"126637","DOI":"10.1016\/j.bmcl.2019.126637","volume":"29","author":"S\u00e1nchez-Mart\u00ednez C.","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez C.; Lallena M.J.; Sanfeliciano S.G.; de Dios A.; Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015\u20132019). Bioorg Med Chem Lett  2019,29(20),126637","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","volume":"164","author":"Cheng W.","year":"2019","unstructured":"Cheng W.; Yang Z.; Wang S.; Li Y.; Wei H.; Tian X.; Kan Q.; Recent development of CDK inhibitors: An overview of CDK\/inhibitor co-crystal structures. Eur J Med Chem  2019,164,615-639","journal-title":"Eur J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1021\/acs.jmedchem.9b02121","volume":"63","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Chen X.; Yan Y.; Zhu X.; Liu M.; Liu X.; Discovery and SARs of 5-Chloro- N4 -phenyl- N2 -(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent antitumor activity. J Med Chem  2020,63(6),3327-3347","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"586826","DOI":"10.3389\/fvets.2020.586826","volume":"7","author":"Su M.","year":"2020","unstructured":"Su M.; Chen Y.; Qi S.; Shi D.; Feng L.; Sun D.; A mini-review on cell cycle regulation of coronavirus infection. Front Vet Sci  2020,7,586826","journal-title":"Front Vet Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"10669","DOI":"10.1074\/jbc.M509233200","volume":"281","author":"Surjit M.","year":"2006","unstructured":"Surjit M.; Liu B.; Chow V.T.K.; Lal S.K.; The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells. J Biol Chem  2006,281(16),10669-10681","journal-title":"J Biol Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41392-022-01296-1","volume":"8","author":"Sui L.","year":"2023","unstructured":"Sui L.; Li L.; Zhao Y.; Zhao Y.; Hao P.; Guo X.; Wang W.; Wang G.; Li C.; Liu Q.; Host cell cycle checkpoint as antiviral target for SARS-CoV-2 revealed by integrative transcriptome and proteome analyses. Signal Transduct Target Ther  2023,8(1),21","journal-title":"Signal Transduct Target Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41392-022-01239-w","volume":"7","author":"Guo S.","year":"2022","unstructured":"Guo S.; Lei X.; Chang Y.; Zhao J.; Wang J.; Dong X.; Liu Q.; Zhang Z.; Wang L.; Yi D.; Ma L.; Li Q.; Zhang Y.; Ding J.; Liang C.; Li X.; Guo F.; Wang J.; Cen S.; SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis. Signal Transduct Target Ther  2022,7(1),400","journal-title":"Signal Transduct Target Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"105558","DOI":"10.1016\/j.antiviral.2023.105558","volume":"212","author":"Xiao Y.","year":"2023","unstructured":"Xiao Y.; Yan Y.; Chang L.; Ji H.; Sun H.; Song S.; Feng K.; Nuermaimaiti A.; Lu Z.; Wang L.; CDK4\/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation. Antiviral Res  2023,212,105558","journal-title":"Antiviral Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"10268","DOI":"10.1021\/acs.jmedchem.6b01301","volume":"59","author":"Ji X.Y.","year":"2016","unstructured":"Ji X.Y.; Chen J.H.; Zheng G.H.; Huang M.H.; Zhang L.; Yi H.; Jin J.; Jiang J.D.; Peng Z.G.; Li Z.R.; Design and synthesis of cajanine analogues against hepatitis C virus through down-regulating host chondroitin sulfate N -Acetylgalactosaminyltransferase 1. J Med Chem  2016,59(22),10268-10284","journal-title":"J Med Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"116069","DOI":"10.1016\/j.ejmech.2023.116069","volume":"265","author":"He Y.","year":"2024","unstructured":"He Y.; Zhou J.; Gao H.; Liu C.; Zhan P.; Liu X.; Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses. Eur J Med Chem  2024,265,116069","journal-title":"Eur J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"115831","DOI":"10.1016\/j.ejmech.2023.115831","volume":"261","author":"Zhou S.","year":"2023","unstructured":"Zhou S.; Wang K.; Hu Z.; Chen T.; Dong Y.; Gao R.; Wu M.; Li Y.; Ji X.; Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors. Eur J Med Chem  2023,261,115831","journal-title":"Eur J Med Chem"},{"key":"ref=97","first-page":"S1","volume":"19","author":"Shavakhi A.","year":"2014","unstructured":"Shavakhi A.; Minakari M.; Bighamian A.; Sadeghian S.; Shavakhi S.; Khamisi N.; Khodadustan M.; Talebi M.; Ataei B.; Statin efficacy in the treatment of hepatitis C genotype I. J Res Med Sci  2014,19(Suppl. 1),S1-S4","journal-title":"J Res Med Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/hep.23204","volume":"50","author":"Rustgi V.K.","year":"2009","unstructured":"Rustgi V.K.; Lee W.M.; Lawitz E.; Gordon S.C.; Afdhal N.; Poordad F.; Bonkovsky H.L.; Bengtsson L.; Chandorkar G.; Harding M.; McNair L.; Aalyson M.; Alam J.; Kauffman R.; Gharakhanian S.; McHutchison J.G.; Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology  2009,50(6),1719-1726","journal-title":"Hepatology"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575311618240820103549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233352\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575311618240820103549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:16:02Z","timestamp":1737018962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233352\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575311618240820103549","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}